Bluebird Bio Inc logo

BLUE - Bluebird Bio Inc Share Price

$46.64 -0.2  -0.4%

Last Trade - 22/01/21

Mid Cap
Market Cap ÂŁ2.26bn
Enterprise Value ÂŁ1.36bn
Revenue ÂŁ182.7m
Position in Universe 1737th / 6630
Unlock BLUE Revenue
Relative Strength (%)
1m -2.58%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -50.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
25.4 14.1 6.16 35.4 54.6 44.7 260.4 143.9 +11.9%
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020,bluebird bio Inc revenues increased from $34.7M to $240M.Net loss decreased 26% to $418.8M. Revenues reflectCollaborative arrangement revenue increase from $29.3M to$114.4M, Royalty and other revenue increase from $5.4M to$17.1M. Lower net loss reflects Change in fair value ofcontingent consi decrease from $1.3M (expense) to $5.6M(income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for BLUE
Graphical History


BLUE Revenue Unlock BLUE Revenue

Net Income

BLUE Net Income Unlock BLUE Revenue

Normalised EPS

BLUE Normalised EPS Unlock BLUE Revenue

PE Ratio Range

BLUE PE Ratio Range Unlock BLUE Revenue

Dividend Yield Range

BLUE Dividend Yield Range Unlock BLUE Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BLUE EPS Forecasts Unlock BLUE Revenue
Profile Summary

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated April 16, 1992
Public Since June 19, 2013
No. of Shareholders: 9
No. of Employees: 1,171
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 66,373,320
Free Float (0.0%)
Eligible for
BLUE Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BLUE
Upcoming Events for BLUE
Tuesday 16th February, 2021 Estimate
Q4 2020 bluebird bio Inc Earnings Release
Monday 10th May, 2021 Estimate
Q1 2021 bluebird bio Inc Earnings Release
Frequently Asked Questions for bluebird bio Inc
What is the bluebird bio Inc share price?

As of 22/01/21, shares in bluebird bio Inc are trading at $46.64, giving the company a market capitalisation of ÂŁ2.26bn. This share price information is delayed by 15 minutes.

How has the bluebird bio Inc share price performed this year?

Shares in bluebird bio Inc are currently trading at $46.64 and the price has moved by -48.02% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the bluebird bio Inc price has moved by -55.54% over the past year.

What are the analyst and broker recommendations for bluebird bio Inc?

Of the analysts with advisory recommendations for bluebird bio Inc, there are there are currently 8 "buy" , 8 "hold" and 0 "sell" recommendations. The overall consensus recommendation for bluebird bio Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will bluebird bio Inc next release its financial results?

bluebird bio Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the bluebird bio Inc dividend yield?

bluebird bio Inc does not currently pay a dividend.

Does bluebird bio Inc pay a dividend?

bluebird bio Inc does not currently pay a dividend.

When does bluebird bio Inc next pay dividends?

bluebird bio Inc does not currently pay a dividend.

How do I buy bluebird bio Inc shares?

To buy shares in bluebird bio Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of bluebird bio Inc?

Shares in bluebird bio Inc are currently trading at $46.64, giving the company a market capitalisation of ÂŁ2.26bn.

Where are bluebird bio Inc shares listed? Where are bluebird bio Inc shares listed?

Here are the trading details for bluebird bio Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: BLUE
What kind of share is bluebird bio Inc?

Based on an overall assessment of its quality, value and momentum, bluebird bio Inc is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a bluebird bio Inc share price forecast 2021?

Shares in bluebird bio Inc are currently priced at $46.64. At that level they are trading at 71.98% discount to the analyst consensus target price of 0.00.

Analysts covering bluebird bio Inc currently have a consensus Earnings Per Share (EPS) forecast of -9.895 for the next financial year.

How can I tell whether the bluebird bio Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like bluebird bio Inc. Over the past six months, the relative strength of its shares against the market has been -38.96%. At the current price of $46.64, shares in bluebird bio Inc are trading at -16.09% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the bluebird bio Inc PE Ratio?

We were not able to find PE ratio data for bluebird bio Inc.

Who are the key directors of bluebird bio Inc?

bluebird bio Inc's management team is headed by:

Nick Leschly - PRE
David Davidson - OTH
Daniel Lynch - CHM
Wendy Dixon - IND
David Schenkein - IND
Jason Cole - COO
Philip Gregory - CSO
John Agwunobi - IND
Alison Finger - OTH
William Baird - CFO
Joanne Smith-Farrell - OTH
Denice Torres - DRC
Katy Burnett - CAO
Ramy Ibrahim - DRC
Who are the major shareholders of bluebird bio Inc?

Here are the top five shareholders of bluebird bio Inc based on the size of their shareholding:

Capital Research Global Investors Investment Advisor
Percentage owned: 12.2% (8.10m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 9.52% (6.32m shares)
American Funds Growth Fund of America Mutual Fund
Percentage owned: 9.37% (6.22m shares)
Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 8.06% (5.35m shares)
Vanguard Health Care Fund Mutual Fund
Percentage owned: 8.04% (5.34m shares)
Similar to BLUE
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.